The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo

• Main Authors: Yuheng Pang (Author), Runze Shi (Author), Liujia Chan (Author), Yu Lu (Author), Di Zhu (Author), Tong Liu (Author), Meisi Yan (Author), Yuji Wang (Author), Wenjing Wang (Author)
• Format: Book
• Published: Elsevier, 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Vorinostat (SAHA) is a histone deacetylase inhibitor that exerts its effects through epigenetic regulation. Specifically, SAHA can inhibit the proliferation of triple-negative breast cancer (TNBC) cells alone or in combination with other chemotherapeutic agents. Doxorubicin (DOX), a traditional chem...